{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:21Z","timestamp":1791228681017,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T00:00:00Z","timestamp":1396051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"BioCARE"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"crossref","award":["2010\/584"],"award-info":[{"award-number":["2010\/584"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Crafoord"},{"name":"Vetenskapsr\u00ef\u00bf\u00bddet","award":["K2012-99-x-22004-01-3"],"award-info":[{"award-number":["K2012-99-x-22004-01-3"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Mantle cell lymphoma (\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    ) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    2\/3 protocols. In 2008, a\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    international prognostic index (\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    ) was created to enable stratification of the clinical diverse\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    patients into three risk groups. So far, use of the\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment\u2010related morbidity, additional parameters need to be evaluated to enable risk\u2010adapted treatment selection. We have investigated the individual prognostic role of the\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    and molecular markers including\n                    <jats:styled-content style=\"fixed-case\">SOX<\/jats:styled-content>\n                    11,\n                    <jats:styled-content style=\"fixed-case\">TP<\/jats:styled-content>\n                    53 (p53),\n                    <jats:styled-content style=\"fixed-case\">MKI<\/jats:styled-content>\n                    67 (Ki\u201067) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    with information on molecular markers.\n                    <jats:styled-content style=\"fixed-case\">SOX<\/jats:styled-content>\n                    11 was shown to significantly add prognostic information to the\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    , but in multivariate analysis\n                    <jats:styled-content style=\"fixed-case\">TP<\/jats:styled-content>\n                    53 was the only significant independent molecular marker. Based on these findings, we propose that\n                    <jats:styled-content style=\"fixed-case\">TP<\/jats:styled-content>\n                    53 and\n                    <jats:styled-content style=\"fixed-case\">SOX<\/jats:styled-content>\n                    11 should routinely be assessed and that a combined\n                    <jats:styled-content style=\"fixed-case\">TP<\/jats:styled-content>\n                    53\/\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    score may be used to guide treatment decisions.\n                  <\/jats:p>","DOI":"10.1111\/bjh.12854","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T02:03:49Z","timestamp":1396058629000},"page":"98-108","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma \u2013 a Nordic Lymphoma Group study"],"prefix":"10.1111","volume":"166","author":[{"given":"Lena","family":"Nordstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Immunotechnology CREATE Health Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sernbo","sequence":"additional","affiliation":[{"name":"Department of Immunotechnology CREATE Health Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Eden","sequence":"additional","affiliation":[{"name":"Department of Astronomy and Theoretical Physics Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"Department of Oncology The Norwegian Radium Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Oncology Helsinki University Central Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja\u2010Liisa","family":"Karjalainen","sequence":"additional","affiliation":[{"name":"Department of Pathology HUCH Laboratory Diagnostics Helsinki University Central Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Ralfki\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Pathology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Laurell","sequence":"additional","affiliation":[{"name":"Department of Oncology Uppsala University Hospital Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Delabie","sequence":"additional","affiliation":[{"name":"Department of Pathology Division of Cancer Medicine and Surgery Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Ehinger","sequence":"additional","affiliation":[{"name":"Department of Pathology University Hospital Lund Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology University Hospital Lund Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ek","sequence":"additional","affiliation":[{"name":"Department of Immunotechnology CREATE Health Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402272"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.140"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.08.001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life\u2010tables","volume":"34","author":"Cox D.R.","year":"1972","journal-title":"Journal of the Royal Statistical Society Series B: Methodological"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.733882"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093401"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-187"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_7_17_1","first-page":"747","article-title":"Nordic MCL3 Study: Zevalin combined with high\u2010dose chemotherapy followed by autologous stem cell support as late intensification for mantle cell lymphoma (MCL) patients < 66\u00a0years not in CR after induction chemoimmunotherapy: no benefit of Zevalin","volume":"120","author":"Kolstad A.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0798-844"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.2892.2892"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010264"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1615"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-269"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400580"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04830.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.72"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452284"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.055715"},{"key":"e_1_2_7_30_1","first-page":"699","article-title":"Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma","volume":"36","author":"Stefancikova L.","year":"2010","journal-title":"International Journal of Oncology"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438937"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07329.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","article-title":"Mantle cell lymphoma\u2013 an entity comes of age","volume":"87","author":"Weisenburger D.D.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_7_35_1","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1\u2010positive MCL and cyclin D1\u2010negative MCL\u2010like B\u2010cell lymphoma","volume":"95","author":"Yatabe Y.","year":"2000","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12854","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.12854","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T09:26:54Z","timestamp":1716629214000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/bjh.12854"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12854","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,29]]},"assertion":[{"value":"2013-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}